Skip to main content
. Author manuscript; available in PMC: 2009 Feb 2.
Published in final edited form as: Clin Pharmacol Ther. 2004 Jan;75(1):34–48. doi: 10.1016/j.clpt.2003.09.004

Fig 1.

Fig 1

Retention in treatment by medication group among 179 cocaine- and opiate-dependent outpatients participating for at least 5 days. Subjects received assigned dose of sublingual buprenorphine for 10 weeks (maintenance phase) and then doses tapering to 0 over a 3-week period (withdrawal phase). qd, Daily; qod, every other day.